Benoit Busser

Paris, 75005, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 46 publications

A Zirconium Aza-BODIPY Derivative as a Near-Infrared Fluorescent/Photoacoustic Imaging Bimodal Probe.

A Zirconium Aza-BODIPY Derivative as a Near-Infrared Fluorescent/Photoacoustic Imaging Bimodal Probe.

Journal: Journal of medicinal chemistry

Published: July 06, 2026

SPECT/NIR Fluorescence Bimodal Use of Aza-BODIPY Probe Coupled with Cetuximab for Detection of Cancer: Proof of Concept on a Preclinical Head and Neck Squamous Cell Carcinoma Model.

SPECT/NIR Fluorescence Bimodal Use of Aza-BODIPY Probe Coupled with Cetuximab for Detection of Cancer: Proof of Concept on a Preclinical Head and Neck Squamous Cell Carcinoma Model.

Journal: Journal of medicinal chemistry

Published: April 21, 2026

In vivo vectorization and delivery systems for gene therapies and RNA-based therapeutics in oncology.

In vivo vectorization and delivery systems for gene therapies and RNA-based therapeutics in oncology.

Journal: Nanoscale

Published: February 10, 2025

Soluble VE-cadherin as a biomarker of response to immunotherapy by anti-PD1 in metastatic melanoma.

Soluble VE-cadherin as a biomarker of response to immunotherapy by anti-PD1 in metastatic melanoma.

Journal: British journal of cancer

Published: December 13, 2024

WazaGaY: An Innovative Aza-BODIPY-Derived Near-Infrared Fluorescent Probe for Enhanced Tumor Imaging.

WazaGaY: An Innovative Aza-BODIPY-Derived Near-Infrared Fluorescent Probe for Enhanced Tumor Imaging.

Journal: Journal of medicinal chemistry

Published: September 18, 2024

Engineering Radiocatalytic Nanoliposomes with Hydrophobic Gold Nanoclusters for Radiotherapy Enhancement.

Engineering Radiocatalytic Nanoliposomes with Hydrophobic Gold Nanoclusters for Radiotherapy Enhancement.

Journal: Advanced materials (Deerfield Beach, Fla.)

Published: March 29, 2024

Comparison of the In Vitro and In Vivo Behavior of a Series of NIR-II-Emitting Aza-BODIPYs Containing Different Water-Solubilizing Groups and Their Trastuzumab Antibody Conjugates.

Comparison of the In Vitro and In Vivo Behavior of a Series of NIR-II-Emitting Aza-BODIPYs Containing Different Water-Solubilizing Groups and Their Trastuzumab Antibody Conjugates.

Journal: Journal of medicinal chemistry

Published: February 23, 2024

NIR-II Aza-BODIPY Dyes Bioconjugated to Monoclonal Antibody Trastuzumab for Selective Imaging of HER2-Positive Ovarian Cancer.

NIR-II Aza-BODIPY Dyes Bioconjugated to Monoclonal Antibody Trastuzumab for Selective Imaging of HER2-Positive Ovarian Cancer.

Journal: Journal of medicinal chemistry

Published: March 30, 2023

Roles of zinc in cancers: From altered metabolism to therapeutic applications.

Roles of zinc in cancers: From altered metabolism to therapeutic applications.

Journal: International journal of cancer

Published: March 30, 2023

Al(III) and Ga(III) Bisphenolate Azadipyrromethene-Based "N2O2" Complexes as Efficient NIR-Fluorophores.

Al(III) and Ga(III) Bisphenolate Azadipyrromethene-Based "N2O2" Complexes as Efficient NIR-Fluorophores.

Journal: Inorganic chemistry

Published: December 21, 2022

Lipoprotein interactions with water-soluble NIR-II emitting aza-BODIPYs boost the fluorescence signal and favor selective tumor targeting.

Lipoprotein interactions with water-soluble NIR-II emitting aza-BODIPYs boost the fluorescence signal and favor selective tumor targeting.

Journal: Biomaterials science

Published: September 23, 2022

Succinimido-Ferrocidiphenol Complexed with Cyclodextrins Inhibits Glioblastoma Tumor Growth In Vitro and In Vivo without Noticeable Adverse Toxicity.

Succinimido-Ferrocidiphenol Complexed with Cyclodextrins Inhibits Glioblastoma Tumor Growth In Vitro and In Vivo without Noticeable Adverse Toxicity.

Journal: Molecules (Basel, Switzerland)

Published: June 15, 2022

Showing 1-12 of 46

Last Updated: 09/26/2026